Compared with 10 European countries, the U.S. spends more to treat cancer patients, but the U.S. has seen greater gains in survival for 11 of 13 cancers during a 16-year period, a new study shows.
The research, published in the journal Health Affairs, estimated the value of the U.S. survival gains totaled $598 billion, or $43 billion annually. That is after subtracting higher U.S. spending, the authors said. The study compared U.S. healthcare spending and cancer survival rates between 1983 and 1999 with those of Finland, France, Germany, Iceland, Norway, Scotland, Slovakia, Slovenia, Sweden and Wales.
"Our study suggests that the higher-cost U.S. system of cancer care delivery may be worth it, although further research is required to determine what specific tools or treatments are driving improved cancer survival in the United States," the authors wrote.